[Secondary prevention after urological tumor diseases. Focusing on the kidneys, testes, and bladder]
Standard
[Secondary prevention after urological tumor diseases. Focusing on the kidneys, testes, and bladder]. / Mathers, M J; Lazica, D A; Klotz, T; Sommer, Frank; Roth, S.
In: UROLOGE, Vol. 46, No. 6, 6, 2007, p. 636-641.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - [Secondary prevention after urological tumor diseases. Focusing on the kidneys, testes, and bladder]
AU - Mathers, M J
AU - Lazica, D A
AU - Klotz, T
AU - Sommer, Frank
AU - Roth, S
PY - 2007
Y1 - 2007
N2 - It is generally agreed upon that patients require a caring as well as careful medical follow-up after cancer treatment. The goal of secondary prevention is to recognize a recurrence at an early stage and to use the curative chance while the tumor mass is still small. There is evidence of a medically effective and successful follow-up for tumors of the testicle and the bladder. For quality reasons, these follow-up regimes should be adhered to for quality reasons. In other diseases, e.g., renal cell carcinoma, prospective randomized studies are missing which demonstrate the effectiveness of follow-ups. In these cases asymptomatic patients should be stratified to individualized follow-up care.
AB - It is generally agreed upon that patients require a caring as well as careful medical follow-up after cancer treatment. The goal of secondary prevention is to recognize a recurrence at an early stage and to use the curative chance while the tumor mass is still small. There is evidence of a medically effective and successful follow-up for tumors of the testicle and the bladder. For quality reasons, these follow-up regimes should be adhered to for quality reasons. In other diseases, e.g., renal cell carcinoma, prospective randomized studies are missing which demonstrate the effectiveness of follow-ups. In these cases asymptomatic patients should be stratified to individualized follow-up care.
M3 - SCORING: Zeitschriftenaufsatz
VL - 46
SP - 636
EP - 641
JO - UROLOGE
JF - UROLOGE
SN - 0340-2592
IS - 6
M1 - 6
ER -
